Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer

Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer

Deficient mismatch repair (dMMR)/microsatellite instability-high (MSIH) colorectal cancer is resistant to conventional chemotherapy but responds to immune checkpoint inhibition (ICI). We review the standard of care in locally advanced dMMR rectal cancer with a focus on ICI. We also present a case re...

Full description

Bibliographic Details
Main Authors: Alan Su, Rodrigo Pedraza, Hagen Kennecke
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Current Oncology
Subjects:
dMMR
immunotherapy
colorectal
PD-1
CTLA-4
Online Access:https://www.mdpi.com/1718-7729/30/4/279

Internet

https://www.mdpi.com/1718-7729/30/4/279

Similar Items